跳转至内容
Merck
所有图片(1)

文件

OP20

Sigma-Aldrich

Anti-c-Abl (Ab-3) Mouse mAb (24-21)

liquid, clone 24-21, Calbiochem®

别名:

Anti-p150, Anti-Abl

登录查看公司和协议定价
所有图片(1)

About This Item

分類程式碼代碼:
12352203
NACRES:
NA.41

生物源

mouse

品質等級

100

抗體表格

purified antibody

抗體產品種類

primary antibodies

無性繁殖

24-21, monoclonal

形狀

liquid

包含

≤0.1% sodium azide as preservative

物種活性

mouse, human

製造商／商標名

Calbiochem®

儲存條件

do not freeze

同型

IgG1

運輸包裝

wet ice

儲存溫度

2-8°C

目標翻譯後修改

unmodified

基因資訊

human ... ABL1(25)

一般說明

Anti-c-Abl (Ab-3), mouse monoclonal, clone 24-21, recognizes the ~145 kDa human and ~150 kDa mouse c-Abl. It is validated for Western blotting, immunofluorescence, and immunoprecipitation.
Purified mouse monoclonal antibody generated by immunizing BALB/c mice with the specified immunogen and fusing splenocytes with p.3U1 mouse myeloma cells (see application references). Recognizes the v-Abl, the ~145-150 kDa c-Abl, the ~210 kDa Bcr-Abl (CML), and the ~190 kDa Bcr-Abl (ALL) proteins.
Recognizes the ~145 kDa human c-Abl, the ~150 kDa mouse c-Abl, v-Abl, and the Bcr/Abl translocation products in ALL (~190 kDa) and CML (~210 kDa). Does not inhibit protein tyrosine kinase activity.
  • Antibody Target Gene Symbol: ABL1
  • Target Synonym: ABL, AI325092, bcr/abl, C-ABL, C-ABL 1B, CABL1, E430008G22Rik, JTK7, MGC117749, p145Abl, p150, v-abl
  • Entrez Gene Name: c-abl oncogene 1, receptor tyrosine kinase
  • Hu Entrez ID: 25 (Related Antibodies: PK1006PK1013OP19)
  • Mu Entrez ID: 11350
  • Rat Entrez ID: 311860

    • 免疫原

    a recombinant protein consisting of the carboxyl region of v-abl protein fused to TrpE

    應用

    Immunoblotting (1-5 µg/ml)

    Immunofluorescence (see application references)

    Immunoprecipitation (1-2 µg/sample)

    Neutralization Studies (not recommended)

    包裝

    Please refer to vial label for lot-specific concentration.

    警告

    Toxicity: Standard Handling (A)

    外觀

    In 0.05 M sodium phosphate buffer, 0.2% gelatin, pH 7.5.

    分析報告

    Positive Control
    K562 (human bcr/abl), HL-60 (normal abl), and ANN-1 (murine abl) cells

    其他說明

    Does not inhibit protein tyrosine kinase activity. Detects human c-Abl (145 kDa), mouse c-Abl (150 kDa), v-Abl, and the Bcr/Abl translocation products in ALL (~210 kDa) and CML (~190 kDa). HL-60 and NIH3T3 cells contain normal, non-rearranged protein. Antibody should be titrated for optimal results in individual sample types.
    Wiedemann, L.M., et al. 1988. Blood71, 349.
    Stam, K., et al. 1985. N. Engl. J. Med.313, 1429.
    Konopka, J.B., et al. 1984. Cell37, 1035.
    Prywes, R., et al. 1983. Cell34, 569.
    de Klein, A., et al. 1982. Nature300, 765.
    Reynolds, F.H., Jr., et al. 1980. J. Virol.36, 374.
    Reynolds, F.H., Jr., et al. 1978. Proc. Natl. Acad. Sci. USA75, 3974.
    Witte, O.N., et al. 1978. Proc. Natl. Acad. Sci. USA75, 2488.
    Abelson, H.T. and Rabstein, L.S. 1970. Cancer Res.30, 2213.

    法律資訊

    CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

    未找到合适的产品？  

    试试我们的产品选型工具.

    儲存類別代碼

    10 - Combustible liquids

    水污染物質分類（WGK）

    nwg

    閃點（°F）

    Not applicable

    閃點（°C）

    Not applicable

    分析证书(COA)

    输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

    已有该产品？

    在文件库中查找您最近购买产品的文档。

    访问文档库

    Tamjeed Saleh et al.
    Nature structural & molecular biology, 24(11), 893-901 (2017-09-26)
    The activity of protein kinases is often regulated in an intramolecular fashion by signaling domains, which feature several phosphorylation or protein-docking sites. How kinases integrate such distinct binding and signaling events to regulate their activities is unclear, especially in quantitative
    Shigeru Matsumura et al.
    Nature communications, 7, ncomms11858-ncomms11858 (2016-06-14)
    Despite theoretical and physical studies implying that cell-extracellular matrix adhesion geometry governs the orientation of the cell division axis, the molecular mechanisms that translate interphase adhesion geometry to the mitotic spindle orientation remain elusive. Here, we show that the cellular
    Cong Fang et al.
    Cancer research, 70(21), 8299-8308 (2010-09-15)
    Oncogenic kinase activity and the resulting aberrant growth and survival signaling are a common driving force of cancer. Accordingly, many successful molecularly targeted anticancer therapeutics are directed at inhibiting kinase activity. To assess kinase activity in minute patient samples, we
    Alexander J M Blakes et al.
    European journal of human genetics : EJHG, 29(4), 593-603 (2020-11-24)
    ABL1 is a proto-oncogene encoding a nonreceptor tyrosine kinase, best known in the somatic BCR-ABL fusion gene associated with chronic myeloid leukaemia. Recently, germline missense variants in ABL1 have been found to cause an autosomal dominant developmental syndrome with congenital
    Martin Frejno et al.
    Molecular systems biology, 13(11), 951-951 (2017-11-05)
    Most molecular cancer therapies act on protein targets but data on the proteome status of patients and cellular models for proteome-guided pre-clinical drug sensitivity studies are only beginning to emerge. Here, we profiled the proteomes of 65 colorectal cancer (CRC)
    查看所有相关文献

    我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

    联系技术服务部门